As developers of gene editing therapies and other genetic medicines get set to report third quarter earnings in coming days, analysts and especially investors will keep their eyes on whether the ...

New to Growth Stocks? Here's 1 Every Investor Should Have on Their Radar. CRISPR Therapeutics has an approved gene-editing ...

Prosper Junior Bakiny has positions in Alphabet, Amazon, and Vertex Pharmaceuticals. The Motley Fool has positions in and ...

As a cornerstone of Indian agriculture and a critical contributor to the national economy and food security across Asia, rice presents both enormous opportunities and pressing challenges. Modern gene ...

The latest in a trend of companies stepping back from cell and gene therapies amid regulatory uncertainty and manufacturing ...

CRISPR Therapeutics recently presented new preclinical data at the ESGCT 2025 Annual Congress showing its investigational CTX460, using the SyNTase gene editing platform, achieved greater than 90% ...

Precision BioSciences (DTIL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further ...

Malaria has haunted humanity for thousands of years, claiming hundreds of thousands of lives every year — mostly children.

Baystreet.ca News Commentary – Longevity science advances reveal how genes from supercentenarians can reverse cardiac aging[1 ...

BioCryst Pharmaceuticals, Inc. acquires Astria Therapeutics for ~$700M, aiming to bolster its HAE portfolio. Learn more about ...

Detailed price information for Cellectis S.A. ADR (CLLS-Q) from The Globe and Mail including charting and trades.

BOSTON, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Fast Company has named Eascra Biotech, a nanomedicine startup, to its annual Next ...